echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Chuangsheng Group's first clinical trial application for the treatment of solid tumors, the Gremlin1 antibody TST003, was approved by the US FDA

    Chuangsheng Group's first clinical trial application for the treatment of solid tumors, the Gremlin1 antibody TST003, was approved by the US FDA

    • Last Update: 2022-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com